Macroaxis: Personalized Investing

Personalized Investing and

Digital Wealth Optimization

GILD    AMGN    BIIB    CELG    Benchmark  United States  NYSE  10,971   95.8545 Index Moved Up 0.8814%  

Processing. Please wait...

Biogen insider: Gregory Covino Biogen insider:  Gregory Covino

   All Insiders        

Chief Accounting Officer, Vice President - Finance

Mr. Gregory F. Covino is Chief Accounting Officer Vice President Finance of Biogen Idec Inc. since April 2012. Prior to that Mr. Covino served at Boston Scientific Corporationrationration a medical device company as Vice President Corporationrationrate Analysis and Control since March 2010 having responsibility for the company internal audit function and as Vice President Finance International from February 2008 to March 2010 having responsibility for the financial activities of the company international division. Prior to that Mr. Covino held several finance positions at Hubbell Incorporated an electrical products company including Vice President Chief Accounting Officer and Controller from 2002 to January 2008 Interim Chief Financial Officer from 2004 to 2005 and Director Corporationrationrate Accounting from 1999 to 2002
Age: 48  President Since 2012      
Gregory Covino Education
Covino received his B.S. in Business Administration from Bryant University.

Management Efficency

The company has return on total asset (ROA) of 18.94 % which means that it generated profit of $18.94 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 30.27 % meaning that it created $30.27 on every $100 dollars invested by stockholders.
The company currently holds 585.2 M in liabilities with Debt to Equity (D/E) ratio of 0.05 which may suggest the company is not taking enough advantage from borrowing. Biogen Idec Inc has Current Ratio of 2.07 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. Biogen Idec Inc [BIIB] is traded on NASDAQ in USA. It is located in Cambridge, MA and employs 7,550 people.

Filter other executives

Specify Title
Indicate Tenure
Select Industry
Click to run this filter
 Run Equity Filter
Filter Other Insiders
Showing few of many executives


George YancopoulosRegeneron Pharmaceuticals Inc
Christian HenryIllumina Inc
Joseph LaRosaRegeneron Pharmaceuticals Inc
Sean HarperAmgen Inc
John MoriartyAlexion Pharmaceuticals Inc
Richard RanieriBioMarin Pharmaceutical Inc
Douglas McCorkleRegeneron Pharmaceuticals Inc
Thorsten GraefPharmacyclics Inc
Saqib IslamAlexion Pharmaceuticals Inc
Peter KelloggCelgene Corporation
Lawrence SteinCelgene Corporation
Nicholas NaclerioIllumina Inc
Matthew PosardIllumina Inc
Frank WrightAlexion Pharmaceuticals Inc
Rainer ErdtmannPharmacyclics Inc
Gregg AltonGilead Sciences Inc
Daniel SpiegelmanBioMarin Pharmaceutical Inc
Amit SachdevVertex Pharmaceuticals Incorpor
Thomas DanielCelgene Corporation
Michael PartridgeVertex Pharmaceuticals Incorpor
Thomas ConnollyVertex Pharmaceuticals Incorpor
NameBiogen Idec Inc
InstrumentUSA Stock
CurrencyUSD - US Dollar
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Biogen Idec Inc to your portfolio

Biogen Idec Leadership

Richard Mulligan, Director
Stelios Papadopoulos, Chairman, Ph.D
George Scangos, CEO, Ph.D
Lynn Schenk, Director
Alexander Denner, Director
Steven Holtzman, President
Paul Clancy, CFO, MBA
Adriana Karaboutis, President
Brian Posner, Director
Stephen Sherwin, Director, Ph.D
Susan Alexander, President
Kenneth Pietro, President
Tony Kingsley, President, MBA
John Cox, EVP, MBA
Gregory Covino, President
Nancy Leaming, Director
Alfred Sandrock, President, Ph.D
Robert Pangia, Director
Caroline Dorsa, Director
Douglas Williams, EVP
Eric Rowinsky, Director, Ph.D
Spyros Artavanis-Tsakonas, President, Ph.D
Adam Koppel, President, MBA
Stuart Kingsley, EVP

Stock Performance

Shares Outstanding234.61 M
Number of Shares Shorted3.13 M